

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

December 22, 2006

David Saliwanchik

David R. Saliwanchik, Patent Attorney

1FW
INFORMATION DISCLOSURE STATEMENT
Examining Group *Not yet assigned*
Patent Application
Docket No. OBI-103CXC1
Serial No. 10/585,790



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : *Not yet assigned*
Art Unit : *Not yet assigned*
Applicant(s) : Francis Chi, Jinxian Xu, Gary Kwan Po Wong
Serial No. : 10/585,790
Filed : July 12, 2006
Conf. No. : *Not yet assigned*
For : Methods for Treating Stress and Affecting Biological Immune Systems
Using a Cysteamine Compound

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed. However, the Applicants have not submitted copies of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

Please note that some of the references cited on the form PTO/SB/08 were cited in the International Search Report of the corresponding International Patent Application. Copies of the International Search Report as well as copies of the cited documents are attached.

Five of the cited references are in a foreign language. The cited references in a foreign language are as follows:

- 1) FR 2,852,959, October 1, 2004;
- 2) JP 2002/187,839, July 5, 2002;
- 3) WO 85/02340, June 6, 1985;
- 4) WO 00/73266, December 7, 2000; and
- 5) Flemming, K. *et al.* (R5).

Please note that references 1-4 have an English abstract; however, Flemming, K. *et al.* does not have an English translation. To meet the duty of disclosure, the applicants have also included a copy of the International Search Report showing the relevancy of the cited reference.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100


Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

DRS/wrc

Enclosures: Form PTO/SB/08 (4 pages)
Copy of International Search Report
References listed therein (31)



PTO/SB/08A (07-05)
Approved for use through 07/31/2006.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/585,790
Filing Date	July 12, 2006
First Named Inventor	Francis Chi
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OBI-103CXC1

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-5,284,874	02-08-1994	Clark <i>et al.</i>	All
	U2	US-5,401,880	03-28-1995	Clark <i>et al.</i>	All
	U3	US-5,605,885	02-25-1997	Bernton <i>et al.</i>	All
	U4	US-5,668,117	09-16-1997	Shapiro	All
	U5	US-5,698,246	12-16-1997	Villamar <i>et al.</i>	All
	U6	US-5,714,519	02-03-1998	Cincotta <i>et al.</i>	All
	U7	US-6,306,453	10-23-2001	Kurzinger	
	U8	US-6,521,266	02-18-2003	Mann	All
	U9	US-6,630,176	10-07-2003	Li <i>et al.</i>	All
	U10	US-6,746,678	06-08-2004	Shapiro	All
	U11	US-11/118,737 (Patent Application)	04-29-2005	Chan <i>et al.</i>	All
	U12	US-2004/033985	02-19-2004	Chi <i>et al.</i>	All
	U13	US-2004/0106591	06-03-2004	Pacioretty <i>et al.</i>	All
	U14	US-2005/0137125	06-23-2005	Chan <i>et al.</i>	All
	U15	US-2005/0143473	06-30-2005	Wong <i>et al.</i>	All
	U16	US-2005/0148674	07-07-2005	Tang <i>et al.</i>	All

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)				
	F1	FR	2 852 959	10-01-2004	Centre National de la Recherche Scientifique Cnrs	Abstract	
	F2	GB	2 245 491	01-08-1992	Medvet Science Pty Ltd.	All	
	F3	GB	2 398 497	08-25-2004	Omega Bio-Pharma	All	
	F4	JP	2002/187,839	07-05-2002	GIFU Internat. Inst of Biotechn	Abstract only	
	F5	WO	85/02340	06-06-1985	Ammon	Abstract	
	F6	WO	95/01096	01-12-1995	Shapiro	All	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/585,790	
			Filing Date	July 12, 2006	
			First Named Inventor	Francis Chi	
			Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	2	of	4	Attorney Docket Number	OBI-103CXC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
	U17				
	U18				
	U19				
	U20				
	U21				
	U22				
	U23				
	U24				
	U25				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³	Number ⁴ – Kind Code ⁵ (if known)			
	F7	WO	96/40099	12-19-1996	Ergo Science Incorporated	All
	F8	WO	00/66110	11-09-2000	Merck Patent GmbH	All
	F9	WO	00/73266	12-07-2000	Centre National de la Recherche Scientifique	Abstract
	F10	WO	01/95944	12-20-2001	Mills	All
	F11	WO	02/076391	10-03-2002	Advanced BioNutrition	All
	F12	WO	2005/060342	07-07-2005	Omega Bio-Pharma	All
	F13	WO	2005/063226	07-14-2005	Omega Bio-Pharma	All
	F14					
	F15					
	F16					
	F17					

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/585,790	
			Filing Date	July 12, 2006	
			First Named Inventor	Francis Chi	
			Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	3	of	4	Attorney Docket Number	OBI-103CXC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BEERS <i>et al.</i> , "Crystal-Induced Conditions," in Merck Manual, Merck Research Laboratories, 1999, pp. 460-464.	
	R2	BERGAMINI, A. <i>et al.</i> , "In vitro Inhibition of the Replication of Human Immunodeficiency Virus Type 1 by Beta-Mercaptoethylamine (Cysteamine)," <i>Journal of Infectious Diseases</i> , 1996, pp. 214-218, Vol. 174, No. 1.	
	R3	BRYANT, H. <i>et al.</i> , "Cysteamine Produces Dose-Related Bidirectional Immunomodulatory Effects in Mice," <i>Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology</i> , 1989, pp. 424-429, Vol. 249, No. 2.	
	R4	FISHER, E. <i>et al.</i> , "Cysteamine in treatment of type III hyperlipidemia?" <i>Lancet</i> , November 20, 1982, pp. 1131-1132, Vol. 2, No. 8308.	
	R5	FLEMMING, K. <i>et al.</i> , "Hemmwirkung Von Cysteamin Auf Den Corticosterongehalt Der Nebennieren Von Ratten Nach Stress-Einwirkung Inhibitory Effect of Cysteamine on the Corticosterone Content of Rat Adrenal Glands After Stress," <i>Experientia</i> , August 15, 1972, pp. 965-966, Vol. 28, No. 8.	
	R6	GYENES, L. <i>et al.</i> , "The Properties of Fragments of Skin-Sensitizing and Blocking Antibodies as Revealed by the Prausnitz-Kuestner, Passive Cutaneous Anaphylaxis and Hemagglutination Reactions," <i>International Archives of Allergy and Applied Immunology</i> , 1964, pp. 106-118, Vol. 24.	
	R7	JEITNER, T. <i>et al.</i> , "Cysteamine and its Phenolic Analogues Inhibit the Proliferation of Normal, Leukemic and Drug Resistant Leukemic T Cells," <i>Free Radical Biology and Medicine</i> , 1990, pp. 172, Vol. 9, Suppl. 1.	
	R8	JEITNER, T. <i>et al.</i> , "Inhibition of the Proliferation of Human Neural Neoplastic Cell Lines by Cysteamine," <i>Cancer Letters</i> , 1996, pp. 85-90, Vol. 103, No. 1,	
	R9	KANO, M. <i>et al.</i> , "Soy milk Products Affect Ethanol Absorption and Metabolism in Rats During Acute and Chronic Ethanol Intake," <i>American Society for Nutritional Sciences</i> , 2002, pp. 238-244.	
	R10	LANDERS, M. <i>et al.</i> , "Permanent-Wave Dermatitis: Contact Allergy to Cysteamine Hydrochloride," <i>American Journal of Contact Dermatitis</i> , 2003, pp. 157-160, Vol. 14, No. 3.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/585,790
				Filing Date	July 12, 2006
				First Named Inventor	Francis Chi
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
				Attorney Docket Number	OBI-103CXC1
Sheet	4	of	4		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R11	REDDY, H. <i>et al.</i> , "Evaluation of the dietary essentiality of vitamins for <i>Penaeus monodon</i> ," <i>Aquaculture Nutrition</i> , December 1999, pp. 267-275, Vol. 5, No. 4.	
	R12	SHIAU, SHI-YEN, <i>et al.</i> , "Dietary pantothenic acid requirement of juvenile grass shrimp, <i>Penaeus monodon</i> ," <i>Journal of Nutrition</i> , March 1999, pp. 718-721, Vol. 129, No. 3.	
	R13	TANAKA <i>et al.</i> , "Protection of Lymphocytes in the Thymus of X-Irradiated Rats by Cysteamine," <i>Nature</i> , April 24, 1965, pp. 418-419, Vol. 206, No. 982.	
	R14	VESCEI <i>et al.</i> , "Preclinical and Clinical Studies with Cysteamine and Pantethine Related to the Central Nervous System," <i>Prg. Neuro-psychopharmacol.</i> , 1990, pp. 835-862, Vol. 14.	
	R15	WALL, T. <i>et al.</i> , "Alcohol Metabolism in Asian American Men with Genetic Polymorphisms of Aldehyde Dehydrogenase," <i>Annals of Int. Med.</i> , 1997, pp. 376-379, Vol. 127, No. 5.	
	R16	WINDHOLZ <i>et al.</i> , "The Merck Index," Tenth Edition, 1983, pp. 849-850.	
	R17	WITTEWER, C.T. <i>et al.</i> , "Pantethine Lipomodulation Evidence for Cysteamine Mediation <i>In vitro</i> and <i>In vivo</i> ," <i>Atherosclerosis</i> , 1987, pp. 41-50, Vol. 68, No. 1-2.	
	R18	ZHU <i>et al.</i> , "Dietary pantothenic acid requirement of juvenile abalone, <i>Haliotis discus hannai</i> Ino," <i>Journal of Shellfish Research</i> , December 2004, pp. 1045-1049, Vol. 23, No. 4.	
	R19		
	R20		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.